AR-1003

N/A

Report date: 2025/07/31 17:26:05
NME

Base Information

Drug NameAR-1003
Drug Alias NameAR-1003
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodiesterase 5A inhibitorsNuclear factor erythroid 2-related factor 2 inhibitors
TargetsPhosphodiesterase 5ANuclear factor erythroid 2-related factor 2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Alzheimer DiseaseSepsis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAribio Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAribio Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Alzheimer DiseaseSepsis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A